ENDOCRINE SOCIETY
OXFORD
Letter to the Editor From Hallanger Johnson and El-Haddad: “Yttrium-90 Selective Internal Radiation Therapy Plus Cryoablation for Recurrent Adrenocortical Carcinoma With Liver Metastases”
Julie Hallanger Johnson10D and Ghassan El-Haddad2(D
1Head and Neck-Endocrine Oncology, Endocrine Program Leader, Moffitt Cancer Center, Tampa, FL 33612, USA 2Diagnostic Imaging and Interventional Radiology, Radionuclide Therapy Program, Moffitt Cancer Center, Tampa, FL 33612, USA
Correspondence: Julie Hallanger Johnson, MD, Associate Member, Head and Neck-Endocrine Oncology, Endocrine Program Leader, Moffitt Cancer Center, 12902 USF Magnolia Drive, Moffitt Cancer Center, Tampa, FL 33612, USA. Email: Julie.hallangerjohnson@moffitt.org.
We read with interest the recent article by Lin et al [1], sharing their experience with yttrium-90 (Y-90) for treatment of adre- nocortical carcinoma (ACC). We fully embrace the opportun- ity to use any and all available treatment options for this rare and devastating illness for which surgical treatments are often the only chance for cure. We wanted to bring our experience and published case to the attention of the authors who state that only 2 cases have been reported. We published our experi- ence [2] in 2021 using Y-90 resin microspheres to treat a gentleman with ACC metastatic to the liver. Our patient opted for surgical resection 7 months after his Y-90 therapy for liver metastasis per multidisciplinary team discussion. At path- ology, there was no viable tumor in the pathology specimen, including the margins, providing confirmation of successful treatment of his hepatic metastases. Our case is the only pub- lished report with proven complete pathologic response post Y-90 radioembolization in a patient with ACC liver metasta- ses. We believe this is an important option to consider for
patients with metastatic ACC which is challenging to treat with effective systemic therapy options.
Disclosures
J.H.J .: HRA Pharma-Consulting fee; G.E .- H .: Bayer HealthCare-Consulting Fee, Boston Scientific Corporation- Consulting Fee, Canon Medical Systems Corporation- Consulting Fee, Novartis Pharmaceuticals Corporation- Consulting Fee, Terumo Medical Corporation-Consulting Fee.
References
1. Lin T, Lin K, Kuo H, et al. Yttrium-90 selective internal radiation therapy plus cryoablation for recurrent adrenocortical carcinoma with liver metastases. J Endocr Soc. 2022;6(8):bvac091.
2. Lu S, Dhillon J, Johnson JH, et al. Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology. EJNMMI Res. 2021;11(1):17.